SafeTy and Outcome of contemPorary Treatment Strategies for Cardiogenic SHOCK

Cardiogenic Shock Clinical Trial

— STOP-SHOCK  

Official title:

SafeTy and Outcome of contemPorary Treatment Strategies for Cardiogenic SHOCK - an International, Observational Registry

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT03313687
• Other study ID #: STOP-SHOCK
• Status: Recruiting
• Start date: September 1, 2017
• Est. completion date: December 31, 2031

Study information

• Verified date: September 2021
• Source: Universitätsklinikum Hamburg-Eppendorf
• Contact: Benedikt Schrage, MD
• Phone: +49 40 7410 18135
• Email: b.schrage[@]uke.de
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

International, observational registry to investigate the outcome in patients with cardiogenic shock. The primary aim of this study is to investigate the clinical outcome of patients in cardiogenic shock.

Description:

There is a focus on interventional therapies, mechanical circulatory support and new cardiovascular therapeutics in patients with cardiogenic shock (CS). The investigators will describe current practice in study sites including concomitant patients with CS. Therefore, the investigators will monitor drug therapies initiated, devices being utilized as well as outcome and side effect of possible interventions

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 2500
• Est. completion date: December 31, 2031
• Est. primary completion date: December 31, 2030
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Patients with cardiogenic shock treated at a tertiary care hospital.

Exclusion Criteria:

• Age =17 years.

Related Conditions & MeSH terms

• Cardiogenic Shock
• Shock
• Shock, Cardiogenic

Locations

Country	Name	City	State
Germany	University Heart Center	Hamburg

Sponsors (1)

Lead Sponsor	Collaborator
Universitätsklinikum Hamburg-Eppendorf

Country where clinical trial is conducted

Germany, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	All-cause mortality	by registration office	Within 30 days after admission.
Secondary	Ischemic events, bleeding events, heart failure, sepsis, dialysis.	by survey, number of ischemic events, number of bleeding events, number of patients developing heart failure as well as heart failure severity (NYHA), patients developing terminal kidney failure requiring dialysis.	Within 30 days after admission.
Secondary	All-cause mortality	by registration office	Within 12 months after admission.
Secondary	Ischemic events, bleeding events, heart failure, sepsis, dialysis.	by survey, number of ischemic events, number of bleeding events, number of patients developing heart failure as well as heart failure severity (NYHA), patients developing terminal kidney failure requiring dialysis.	Within 12 months after admission.